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MicroRNAs (miRNAs) are an emerging class of non-coding
endogenous RNAs involved in multiple cellular processes, in-
cluding cell differentiation. Treatment with retinoic acid (RA)
results in neural differentiation of neuroblastoma cells. We
wanted to elucidate whether miRNAs contribute to the gene
expression changes induced by RA in neuroblastoma cells and
whether miRNA regulation is involved in the transduction of
the RA signal. We show here that RA treatment of SH-SY5Y
neuroblastoma cells results in profound changes in the expres-
sion pattern of miRNAs. Up to 42 different miRNA species
significantly changed their expression (26 up-regulated and 16
down-regulated). Among them, the closely related miR-10a
and -10b showed the most prominent expression changes. In-
duction of miR-10a and -10b by RA also could be detected in
LA-N-1 neuroblastoma cells. Loss of function experiments
demonstrated that miR-10a and -10b are essential mediators
of RA-induced neuroblastoma differentiation and of the asso-
ciated changes in migration, invasion, and in vivometastasis.
In addition, we found that the SR-family splicing factor SFRS1
(SF2/ASF) is a target for miR-10a -and -10b in HeLa and SH-
SY5Y neuroblastoma cells. We show here that changes in miR-
10a and -10b expression levels may regulate SFRS1-dependent
alternative splicing and translational functions. Taken to-
gether, our results give support to the idea that miRNA regula-
tion plays a key role in RA-induced neuroblastoma cell differ-
entiation. The discovery of SFRS1 as direct target of miR-10a
and -10b supports the emerging functional interaction be-
tween two post-transcriptional mechanisms, microRNAs and
splicing, in the neuronal differentiation context.
MicroRNAs (miRNAs, miRs)5 are an emerging class of
small non-coding endogenous RNAs that are involved in mul-
tiple biological processes. These tiny regulatory elements are
transcribed as primary longer transcripts, which are then pro-
cessed by Dicer and Drosha complexes into 21–23-nt mature
miRNAs. One strand of the mature miRNA is then incorpo-
rated into the RNA-induced silencing complex to regulate
gene expression by targeting the 3-untranslated region (3-
UTR) of mRNAs with consequent translational repression
and/or target mRNA degradation. This mode of action dem-
onstrates the great regulatory potential of miRNAs, as a
unique mRNA can be targeted by diverse miRNAs, and con-
versely, each miRNA may have 100s of different target
mRNAs (for review, see Refs. 1 and 2).
In vertebrates, the highest variety of miRNAs is ex-
pressed in the brain than in any other tissue, suggesting an
important role in nervous system development (3, 4). Re-
cent studies have revealed the importance of miRNA ex-
pression in neural development and differentiation. For
instance, it has been reported that Dicer-deleted mice ex-
hibit malformations of the midbrain and cerebellum and
failure of neural crest and dopaminergic differentiation (5).
In addition, three brain-specific miRNAs (miR-124a,
miR-9, and miR-132) have been proposed to regulate the
transcription factor REST that mediates neuronal identity
(6), and miR-132 seems also to be involved in the control of
neuronal morphogenesis by decreasing the GTPase-acti-
vating protein, p250GAP (7). Conversely, de-regulation of
miRNA action contributes to different pathological pro-
cesses, including cancer (8, 9). In recent years miRNAs
have been established as important regulators of tumor
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development, progression, and metastasis and have dem-
onstrated to be useful for tumor diagnosis and classifica-
tion. Moreover, miRNA regulation might represent a new
avenue for cancer treatment in a near future (10–14).
Neuroblastoma is the most common extracranial solid tu-
mor in childhood and the most common tumor in infants,
which originates from aberrant development of primordial
neural crest cells (15, 16). Despite their tumor origin, neuro-
blastoma cell lines can be induced to differentiate in vitro by
several agents, including retinoic acid (RA) (17–19). Adminis-
tration of RA to neuroblastoma cells in vitro leads to prolifer-
ative arrest and neuronal differentiation as judged by their
morphology and the expression of biochemical and functional
neuronal markers (20, 21). In addition, to inhibit cell prolifer-
ation and induce differentiation, long term RA treatment re-
duces the biological aggressiveness of neuroblastoma cells by
reducing their migratory and invasive abilities (22, 23). All
these results prompted the introduction of RA and its deriva-
tives into therapeutic protocols for neuroblastoma patients,
with some success especially in the treatment of minimal re-
sidual disease (24–26). Although several evidences support a
role for miRNAs in neuroblastoma pathogenesis (27–30) and
the usefulness of miRNA profiles for neuroblastoma diagnos-
tics, classification, and prognosis has been recently reported
(31–33), little is known about the involvement of miRNAs in
RA-induced differentiation of neuroblastoma cells.
In this study we show that RA treatment of SH-SY5Y neu-
roblastoma cells results in profound changes in the expression
pattern of miRNAs. Up to 42 different miRNA species signifi-
cantly change their expression levels (26 up-regulated and 16
down-regulated). Among them, the closely related miR-10a
and -10b showed the most prominent expression changes.
Through loss of function experiments we could show that
miR-10a and -10b contribute to the regulation of RA-induced
differentiation and in the associated changes in migratory and
invasive activities. In addition we could determine that the
SR-family splicing factor SFRS1 (SF2/ASF) is a target for miR-
10a and -10b action, and we show that changes in miR-10a
and -10b expression levels may influence cellular processes in
which SFRS1 is involved. Our results give support to the idea
that miRNA regulation plays a key role in RA-induced neuro-
blastoma cell differentiation and in the associated gene ex-
pression changes.
EXPERIMENTAL PROCEDURES
Cell Culture and RA Treatment—SH-SY5Y (ATCC CRL-
2266) and HeLa (ATCC CCL-2) cells were cultured in DMEM
containing 10% heat-inactivated FBS, 100 units/ml penicillin,
and 100 g/ml streptomycin. LA-N-1 cells (European Collec-
tion of Animal Cell Cultures ECACC 06041201) were grown
on gelatin-coated plastic dishes in a 1:1 mixture of EMEM and
Ham’s F-12 medium containing 15% heat-inactivated FBS,
100 units/ml penicillin, 100 g/ml streptomycin, and 1% non-
essential amino acids. Cell cultures were kept at 37 °C in a
humidified atmosphere with 5% CO2. The medium was re-
placed every 2 days, and the cells were split before they
reached confluence. RA (all-trans retinoic acid, Sigma) was
dissolved in dimethyl sulfoxide and added to the culture me-
dium at 1 M concentration.
miRNA Expression Profiling—For miRNA expression, pro-
filing real-time RT-PCR was performed using TaqMan Hu-
man MicroRNA Low Density Arrays Version 2.0 (Applied
Biosystems). A comprehensive coverage of Sanger miRBase
v10 is enabled across the two-card set of TaqMan MicroRNA
arrays for a total of 667 unique assays specific to human miR-
NAs. In addition, each array contains four control assays,
three endogenous control assays and one negative control
assay. SH-SY5Y cells were treated with 1 M RA during 0, 24,
48, and 96 h (4 replicate 100-mm dishes for each condition).
Total RNA was extracted using the mirVana kit (Ambion-
Applied Biosystems) and quantified by spectrophotometry
and the integrity of the RNA evaluated in agarose gels. Retro-
transcription, pre-amplification, and real-time PCR of miR-
NAs were made following the Megaplex Pools for microRNA
Expression Analysis Protocol. All reagents were obtained
from Applied Biosystems. Both reverse transcription and pre-
amplification were made with two different pools of primers
(A and B), corresponding to the miRNAs represented in the
array A and B, respectively. 1 g of total RNA was reverse-
transcribed using Megaplex RT primers and the TaqMan
miRNA reverse transcription kit in a total of 7.5 l volume.
Then the reverse-transcribed product (2.5 l) was pre-ampli-
fied using Megaplex PreAmp Primers and TaqMan PreAmp
Master Mix in a 25-l reaction. The pre-amplified cDNA was
diluted 1:4 with 0.1 Tris-EDTA, pH 8.0, and quantitative
real-time PCR was performed using Applied Biosystems
7900HT system and a TaqMan Universal PCR Master Mix
with 9 l of diluted cDNA input per plate.
Data from real-time RT-PCRs were analyzed using the Ap-
plied Biosystems 7900HT Fast Real-Time PCR System Rela-
tive Quantitation Using Comparative Ct in SDS v2.2 software.
The experimental data have been analyzed with the automatic
base line and manual Ct set to 0.2. The amplification plots
have been reviewed manually and the base-line and the
threshold settings adjusted for individual assays, if necessary.
Because a Ct value of 35 represents single molecule template
detection, Ct values35 were considered to be below the
detection level of the assay. Therefore, only the miRNAs with
a Ct 35 were included in the analyses. A moderate t test
between all treated versus non-treated groups was performed
and corrected using the Benjamini-Hochberg algorithm with
the false discovery rate set at a value of 5%.
Anti-miR and Pre-miR Transfection—SH-SY5Y cells were
seeded at 500,000 cells/well in 6-well plates. On the next day,
the cells were transfected with one of the RNA oligonucleo-
tides (anti-miR-10a, anti-miR-10b, negative control anti-miR,
pre-miR-10a, pre-miR-10b, and negative control pre-miR;
Ambion-Applied Biosystems) at 50 nM final concentration
using 5 l of Lipofectamine 2000 reagent (Invitrogen) and
Opti-MEMmedium. After 6 h of transfection, the medium
was changed to fresh SH-SY5Y growth medium with 1 M RA
or vehicle. HeLa cells were seeded at 250,000 cells/well in
6-well plates and transfected as described above for SH-SY5Y
cells.
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Luciferase Reporter Assays—The 3-UTRs of the putative
target genes (SFRS1 and SFRS10) were amplified by PCR and
cloned downstream to the luciferase reporter gene into the
XbaI site of pGL3-Control vector (Promega). Reporter genes
were sequenced to assess the right sequence and orientation
of the fragments. HeLa cells were seeded at 50,000 cells/well,
and the following day, 500 ng of luciferase reporter construct
(SFRS1 3-UTR or SFRS10 3-UTR) and 25 ng of Renilla lucif-
erase reporter construct as internal control were co-trans-
fected together with one of the RNA oligonucleotides at a 50
nM final concentration using 3 l of Lipofectamine 2000 rea-
gent (Invitrogen) and Opti-MEMmedium as described above.
After 48 h the cells were lysed, and firefly and Renilla lucifer-
ase activities from cell extracts were measured with the dual-
luciferase reporter system (Promega) according to the manu-
facturer’s instructions. The effects of miRNA regulation on
SFRS1-mediated translational regulation were analyzed with
reporter plasmids pLCS-EDAwt and pLCS-EDAmt (34), which
were transfected as described (35) together with one of the
RNA oligonucleotides at a 50 nM final concentration.
Quantitative Real-time Reverse Transcription PCR—Total
RNA was extracted from SH-SY5Y, HeLa, and LA-N-1 cells
using TRIzol reagent (Invitrogen) and then quantified by
spectrophotometry. For quantitative real-time PCR of
miRNA, 10 ng of total RNA was reverse-transcribed in a
15-l total reaction volume using specific stem-loop RT
primers (Applied Biosystems), and 1.33 l of cDNA was sub-
jected to a TaqMan miRNA assay (Applied Biosystems) in 20
l of total reaction using primers and probe specific for indi-
vidual human miRNAs according to the manufacturer’s pro-
tocol. Expression values were calculated using the compara-
tive Ct method, and U6 snRNA was used as an endogenous
control. For quantitative real-time PCR of mRNAs, 1 g of
total RNA was reverse-transcribed using oligo(dT)16 and
Moloney murine leukemia virus reverse transcriptase as de-
scribed (36). 1 l of a 10-fold cDNA dilution was subjected to
SYBR Green or TaqMan gene expression assays (Applied Bio-
systems) according to the manufacturer’s instructions. Ex-
pression values were also calculated using comparative Ct
method, and GAPDH gene was used as endogenous control.
Reactions were run in an Applied Biosystems 7500 Fast Real-
Time PCR system.
Proliferation Assays—For [3H]thymidine incorporation as-
says, SH-SY5Y cells were seeded in 24-well plates at 50,000
cells/well and transfected the following day with anti-miR-
10a, anti-miR-10b, or negative control anti-miR at 50 nM final
concentration using 1 l of Lipofectamine 2000 reagent (In-
vitrogen) and Opti-MEMmedium as described above. After
6 h of transfection, the medium was changed to fresh SH-
SY5Y growth medium supplemented with 1 M RA or vehicle.
After 96 h of RA treatment, cells were pulse-labeled for 6 h
with 1 Ci/ml of [3H]thymidine deoxyribose (5 Ci/mmol,
Amersham Biosciences). The cells were then harvested with
10% TCA by shaking for 10 min and processed for liquid scin-
tillation counting. For the determination of DNA content SH-
SY5Y cells were transfected with anti-miR-10a, anti-miR-10b,
or negative control anti-miR in 6-well plates as described
above. After transfection, the medium was changed to fresh
SH-SY5Y growth medium with 1 M RA or vehicle. After 96 h
of RA treatment the cells were washed in PBS and fixed in
80% ethanol for 60 min at 4 °C. The cells were then washed
with PBS and treated with DNA extraction buffer (0.2 M
Na2HPO4, 0.1 M citric acid, pH 7.8) for 5 min at 37 °C. Sam-
ples were centrifuged, and cellular DNA was stained with 20
g/ml propidium iodide (Sigma) and 0.2 mg/ml DNase-free
RNase A (Sigma) in PBS for 30 min at 37 °C in the dark. After
cytometry in a FACSCanto cytometer (BD Biosciences), the
cell cycle phases were determined by using the ModFit LT 3.0
package.
Western Blot—Cells were washed with PBS and lysed in
radioimmune precipitation assay buffer (50 mM HEPES pH
7.4, 150 mM NaCl, 1 mM EGTA, 10 mM NaF, 0,5% Nonidet
P-40, 1 mM sodium orthovanadate, 10 g/ml leupeptin, 10
g/ml aprotinin, 100 M PMSF). The extract was cleared by
centrifugation at 4 °C, and the protein content was deter-
mined with Bio-Rad protein assay. Western blot was per-
formed as described (37). Antibodies against tyrosine hydrox-
ylase were obtained from Cell Signaling Technologies, those
against ID2 and SFRS1 were purchased from Santa Cruz Bio-
technology, and those against -actin and NEFM were ob-
tained from Sigma. Horseradish peroxidase-conjugated sec-
ondary antibodies were obtained from GE Healthcare.
Migration and Invasion Assays—The migration and inva-
sion capacities of SH-SY5Y neuroblastoma cells were tested
according to published protocols (38, 39) with slight modifi-
cations. A modified, light-opaque Boyden chamber (Falcon
HTS FluoroBlock, 8 m pore size; BD Biosciences) was used
in migration assays. SH-SY5Y cells were transfected with 50
nM negative control anti-miR, anti-miR-10a, or anti-miR-10b,
respectively, and treated with 1 M RA for 96 h. After 96 h of
treatment, cells were labeled in the plate with calcein AM (5
M; Molecular Probes-Invitrogen) for 30 min at 37 °C. La-
beled cells were detached from the plate by scraping and
counted. For migration assays, the lower chamber of the plate
contained 10% FBS as chemo-attractant. 5 104 labeled cells
in serum-free medium were added onto the upper chamber.
After 6 h of incubation at 37 °C, the fluorescent light emitted
by the cells that migrated through the opaque filter was mea-
sured with a Victor2 multilabel counter (PerkinElmer Life Sci-
ences). The assays were performed in triplicate. For invasion
assays SH-SY5Y cells were transfected with 50 nM negative
control anti-miR, anti-miR-10a, or anti-miR-10b, respectively,
and treated with 1 M RA or vehicle for 96 h after the above
protocol. After 96 h of treatment, cells were trypsinized, and
0.3 106 cells were transferred to transwell chambers pre-
coated with 10 g Matrigel (BD Biosciences) matrix. Me-
dium containing 10% FBS in the lower chamber served as
chemo-attractant. Plates were incubated for 24 h. After 24 h
of incubation, the invading cells were detached from the bot-
tom of the membrane by placing the 24-well inserts in 24-well
plates prepared with 500 l trypsin/well and incubating them
at 37 °C for 10 min. Non-invading cells from the top of the
membrane were removed using 200 l of trypsin. Invading
and non-invading cells were transferred to 1.5-ml tubes and
centrifuged at 1200 rpm for 5 min to remove the trypsin.
Then, cells in each well were resuspended in 50 l of Cell
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Titer-Glo reagent (Promega), and lysates were plated in 96-
well plate. The luminescence signal was read according to the
manufacturer’s instructions, and the invasion ratio from
the three replicates were calculated and expressed as the
mean S.D.
Chicken Chorioallantoic Membrane Assay—The chicken
chorioallantoic membrane assay was performed as described
previously (40, 41). In brief, negative control anti-miR- or
anti-miR-10a-transfected cells were treated with 1 M RA or
vehicle for 96 h. Then, 1 106 cells were placed on the upper
chorioallantoic membrane of 10-day-old chicken embryos.
After 7 days the chicken embryos were dissected, and the
quantification of the metastatic cells was performed on
genomic DNA from embryonic lungs prepared using the
Puregene DNA purification system (Qiagen). Quantification
of human Alu sequences in the extracted DNA was per-
formed by TaqMan quantitative PCR as described (42). Six
parallel assays were performed for each condition.
Statistical Analysis—Pairwise comparisons between sample
groups were analyzed by the one-tailed Student’s t test, with
statistically significant differences between the means indi-
cated as p 0.05 (*), p 0.01 (**), or p 0.001 (***).
RESULTS
miRNA Expression Profiling during RA-induced Differentia-
tion of Neuroblastoma SH-SY5Y Cells—We wanted to under-
stand the contribution of microRNAs to the gene expression
changes occurring during RA-induced differentiation of hu-
man neuroblastoma cells. With this aim we have analyzed the
changes in the miRNA expression profile of SH-SY5Y cells
upon treatment with 1 M RA for 0, 24, 48, and 96 h. For this
purpose, we used TaqMan Human MicroRNA Low Density
Arrays v2.0 (Applied Biosystems), which provide comprehen-
sive coverage of Sanger miRBase v10 for a total of 667 unique
assays specific to human miRNAs. The data from real-time
RT-PCRs were analyzed through the Relative Quantitation
Using Comparative Ct method. The data were normalized
against U6 snRNA, and a moderate t test and a correction
using the Benjamini-Hochberg algorithm with the false dis-
covery rate set at a value of 5% was performed between all the
treated versus non-treated comparisons. On the basis of this
analysis, 452 human miRNAs could be detected, whereas 215
did not reach the detection threshold. Among those, 452
miRNAs present, 42 showed a statistically significant change
in expression at least in two of the three treated versus un-
treated comparisons (Fig. 1A). From these 42 miRNAs, a set
of 26 miRNAs was up-regulated, and a group of 16 miRNAs
was down-regulated during the RA treatment (Fig. 1, B and
C). Among the up-regulated group we found that miR-10a,
-10b, -10b*, -615–5p, -211, -212, -132, -22, -766, -135a, and
-148b* had a robust pattern of induction. On the other hand
we found miR-490–3p, -154*, 26a-2*, -296–3p, -422a, -486–
3p, -378, -411*, -543, -801, -873, and -107 had a robust pat-
tern of down-regulation. The expression of the 12 miRNAs
with most prominent changes was validated by real-time RT-
PCRs using Applied Biosystems TaqMan individual specific
assays to human miRNAs (Fig. 1, D and E). All the validated
miRNAs showed significant change in their expression, con-
firming to the pattern observed in the array data. Among the
group of differentially expressed miRNAs, two members of
miR-10 family, miRNA-10a and -10b, were strongly up-regu-
lated and showed a similar pattern of induction. Induction of
miR-10a and -10b by RA occurred to comparable levels in
another human neuroblastoma cell line, LA-N-1 (Fig. 1, F
and G).
Suppression of miR-10a and -10b Endogenous Expression
Results in Impairment of RA-induced Differentiation—To
gather information about the roles of miR-10a and -10b in
RA-induced neuroblastoma differentiation, we have per-
formed loss of function experiments with antisense miRNA
antagonists (anti-miRs) and evaluated their effects on the
morphology, the proliferation rate, and the expression of dif-
ferentiation and neuronal markers in neuroblastoma cells.
After transfection of each specific anti-miR to SH-SY5Y cells
and treatment with RA, near 60% of reduction of miRNA-10a
and -10b endogenous levels was achieved (Fig. 2F). Cells in
which the expression of miR-10a and -10b was reduced with
specific anti-miRs showed impaired differentiation. Untreated
neuroblastoma cells bear short neurites and grow as high den-
sity cell clusters. Upon RA treatment, extension of neurites
took place, and the cells spread on the plate surface. When
anti-miR-10a/-10b were transfected and the cells treated with
RA, a reduction in the length of neurites and an increase in
the cell cluster number could be observed as compared with
cells transfected with negative control anti-miR (Fig. 2, A–E).
Quantification of neurite length using Neuron J software (43)
show that RA treatment of cells transfected with anti-miR-
10a or -10b resulted in reduced neurite length, as compared
with cells transfected with negative control (NC)-anti-miR
(Fig. 2G). RA treatment of neuroblastoma cells also results in
proliferative arrest, and the effects of miR-10a and -10b sup-
pression on proliferation of SH-SY5Y cells have been ana-
lyzed. Treatment of neuroblastoma cells with RA for 96 h led
to a strong reduction of the incorporation of [3H]thymidine to
30% of the control values. However, this reduction of the
proliferation was equally observed in RA-treated cells trans-
fected with anti-miR-10a or -10b (Fig. 2G). Consequently, the
percentage of cells in S-phase is reduced to half as the effect
of RA treatment for 96 h, evaluated after cytometry of pro-
pidium iodide-stained cells. After transfection of miR-10a
or-10b, a similar reduction in the fraction of cells in S-phase
could be observed (Fig. 2H). Finally, we have tested whether
the suppression of miR-10a and -10b would affect apoptosis
of neuroblastoma cells. By analyzing the cellular DNA content
by means of cytometry in propidium iodide-stained cells, we
could not detect an increase in sub-G1 cell population after
transfection of anti-miR-10a or -10b, supporting the idea that
miR-10a and -10b are not involved in the regulation of apo-
ptosis (data not shown).
The role of miRNA-10a and -10b in promoting the differ-
entiation of SH-SY5Y cells was further demonstrated by eval-
uating the effect of specific anti-miRs on the expression of
differentiation markers. Tyrosine kinase receptors NTRK2
(trkB) and RET are induced by RA in several neuroblastoma
cells lines and have been proposed to play important roles in
differentiation (44–49). The levels of NTRK2 and RET
miR-10a and -10b in RA-induced NeuroblastomaDifferentiation
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FIGURE 1.miRNA expression profiling in differentiating SH-SY5Y cells is shown. A, shown is a summary of TaqMan microRNA LDA expression
profiling results. B and C, relative expression values are detected in TaqMan microRNA LDA for microRNAs with a false discovery rate of 0.05 at
least in two of the three treated versus non-treated comparisons, for up-regulated (B) and down-regulated miRNAs (C). The values for 24 h (empty
bars), 48 h (gray bars), and 96 h (black bars) of RA treatment are represented. D and E, RT-qPCR validation experiments for selected up-regulated (D)
and down-regulated (E) microRNAs are shown. Data were normalized for the expression of U6 small nuclear RNA, and the relative expression level to
the value of 0 h of RA treatment is represented (mean S.D. from the two independent determinations). The values for 0 h (empty bars), 24 h (light
gray bars), 48 h (dark gray bars), and 96 h (black bars) of RA treatment are shown. F and G, expression levels of miR-10a (F) and -10b (G) during RA
treatment of SH-SY5Y and LA-N-1 neuroblastoma cells are shown. The cells were treated with RA for the times indicated in the figure, and the levels
of miR-10a and -10b were analyzed by RT-qPCR as indicated for D and E. The graph shows the mean  S.D. from two independent determinations.
Black bars, SH-SY5Y cells. Gray bars, LA-N-1 cells.
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mRNAs were very low in untreated SH-SY5Y cells, and RA
treatment led to strong induction of the expression of both
genes. However, RA treatment of anti-miR-10a- and anti-
miR-10b-transfected cells resulted in a reduction of NTRK2
and RET gene expression, as compared with negative control
anti-miR transfected cells (Fig. 3, A and B). GAP43 and neu-
ron-specific enolase (ENO2) have been also reported as neu-
ronal differentiation markers (18, 46, 50). GAP43 and ENO2
mRNA basal levels were somewhat higher in untreated SH-
SY5Y cells, although a modest increase could be detected af-
ter RA treatment. This increase was nevertheless abolished in
anti-miR-10a and anti-miR-10b transfected cells but not in
cells transfected with negative control anti-miR (Fig. 3, C and
D).The members of the ID gene family, ID1, ID2, and ID3, are
basic helix-loop-helix transcription factors that act as impor-
tant negative regulators of differentiation (51, 52), and their
down-regulation during RA treatment in SH-SY5Y has been
previously reported (50, 53). RA treatment of anti-miR-10a-
and anti-miR-10b-transfected cells resulted in impairment of
ID1, ID2, and ID3 gene down-regulation, as compared with
negative control anti-miR-transfected cells (Fig. 3, E, F, and
G). These alterations in mRNA levels were paralleled by ele-
vated ID protein levels, as shown as an example in the case of
ID2 by Western blot (Fig. 4A). In addition, we have evaluated
by Western blot the expression of other common neuronal
markers positively regulated upon RA treatment in SH-SY5Y
FIGURE 2. Experimental reduction of miR-10a and -10b levels impaired RA-inducedmorphological differentiation without altering proliferation
arrest. A–E, morphological differentiation induced by RA was impaired after experimental reduction of miRNA-10a and -10b levels. Photomicrographs of
untransfected cells treated with vehicle (A, ut), untransfected cells treated with RA for 96 h (B, RA), cells transfected with negative control anti-miR and sub-
sequently treated with RA as above (C, NC-amRA), or cells transfected with anti-miR-10a or -10b and subsequently treated with RA as above (am-10aRA
(D) and am- 10bRA (E), respectively) are shown. F, shown is RT-qPCR analysis of miRNA-10a and -10b expression levels after transfection of SH-SY5Y cells
with anti-miR-10a, -10b and NC anti-miR and subsequent RA treatment for 96 h. For comparison, the values obtained with mock-transfected cells treated
with vehicle (mock) or RA (mockRA) are shown. The graph represents the values obtained from a triplicate experiment (mean S.D.). Statistical signifi-
cance was analyzed by comparing samples transfected with anti-miR-10a or -10b with those transfected with NC-anti-miR. G, miR-10a or -10b knockdown
results in reduced RA-induced neurite outgrowth. Quantification of neurite length was performed with Neuron J software (43) on photomicrographs ob-
tained after transfection of SH-SY5Y cells with anti-miR-10a and -10b and NC anti-miR and subsequent RA treatment for 96 h. For comparison, the values
obtained with mock-transfected cells treated with vehicle (mock) or RA (mockRA) are shown. The graph represents the values obtained (mean S.E.). At
least 100 cells from duplicate photomicrographs were analyzed for each condition. Statistical significance was analyzed by comparing samples transfected
with anti-miR-10a or -10b with those transfected with NC-anti-miR. H and I, suppression of miR-10a and -10b expression did not affect the proliferation ar-
rest induced by RA. G, [3H]thymidine incorporation in control mock-transfected SH-SY5Y neuroblastoma cells and after RA treatment for 96 h of mock-trans-
fected cells or cells transfected with NC-anti-miR, anti-miR-10a, or anti-miR-10b. The graph represents the values obtained from triplicate experiments
(mean S.D.). Statistical significance was analyzed by comparing samples transfected with anti-miR-10a or -10b with those transfected with NC-anti-miR.
a.u., arbitrary units. H, shown is the effect of RA treatment and miR-10a or -10b knockdown in the fraction of cells at the S phase of the cell cycle. The per-
centage of cells in S phase was obtained by analyzing the DNA content by cytometry after staining with propidium Iodide. The effects of RA treatment in
cells transfected with NC-anti-miR, anti-miR-10a, or anti-miR-10b were compared with those observed in mock-transfected cells.
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cells, as the medium-size neurofilament protein NEFM (46)
and the enzyme tyrosine hydroxylase, involved in the biosyn-
thesis of catecholamine (54, 55). RA treatment of SH-SY5Y
cells after miR-10a and -10b reduction by anti-miR transfec-
tion resulted in impaired NEFM up-regulation, as shown by
Western blot (Fig. 4B). Similarly, RA-induced expression of
tyrosine hydroxylase was partially abolished in anti- miR-10a-
and -10b-transfected cells (Fig. 4C). In summary, our results
indicate that miR-10a and -10b were involved in RA-induced
neurite outgrowth and in the gene expression changes associ-
ated with neural differentiation. However, miR-10a and -10b
did not appear to play a relevant role in RA-induced prolifera-
tion arrest.
We have tested whether the overexpression of miR-10 and
-10b, by transfecting their cognate precursor pre-miRs, would
affect the expression of differentiation markers independently
of RA treatment. The mRNA levels of RET, NTRK2, GAP43,
and ENO2 were slightly enhanced by transfection of pre-miR-
10a and -10b, as compared with transfection of negative con-
trol pre-miR. Similarly, the levels of NEFM and tyrosine
FIGURE 3. Experimental reduction of miR-10a and -10b levels impaired gene expression changes associated with RA-induced differentiation.
RT-qPCR analysis of the mRNA levels of NTRK2 (trkB, A), RET (B), GAP43 (C), ENO2 (neuron-specific enolase, D), ID1 (E), ID2 (F), and ID3 (G) is shown.
mRNA expression levels after RA treatment of SH-SY5Y cells transfected with anti-miR-10a and -10b or negative control anti-miR. For comparison,
the values obtained with mock-transfected cells treated with vehicle (mock) or with RA (mockRA) are shown. The graph represents the values ob-
tained from triplicate experiments (mean  S.D.). Statistical significance was analyzed by comparing samples transfected with anti-miR-10a or -10b
with those transfected with NC-anti-miR.
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hydroxylase proteins were enhanced by overexpression of
pre-miR-10a and -10b, as compared with negative control
pre-miR (see supplemental Fig. S1). However, the attained
expression levels for all the markers analyzed are far below
those obtained by RA treatment. Therefore, miR-10a and
-10b appeared to be necessary but not sufficient for full neural
differentiation, and consequently, additional actions of RA
must contribute to differentiation.
Knockdown of miR-10a and -10b Impaired the RA-induced
Reduction of Migratory and Metastatic Abilities of Neuroblas-
toma SH-SY5Y Cells—Other important cellular processes in
which miR-10a and miR-10b could play a role are migration,
invasion, and metastasis. It has been shown that long term RA
treatment reduces the biological aggressiveness of neuroblas-
toma cells by reducing their migratory and invasive abilities
(22, 23), and we wanted to know whether the induction of
miR-10a and miR-10b by RA could participate in this reduced
migratory and invasive behavior. We first analyzed the migra-
tory ability of anti-miR-transfected RA-treated neuroblas-
toma cells using a transwell migration assay and FBS as
chemo-attractant. As is shown in Fig. 5A, RA treatment re-
sults in reduced migration, whereas blocking miR-10a and
-10b function by co-transfecting the cognate anti-miRs abol-
ished the reduction in migration induced by RA in SH-SY5Y
cells. Invasive activity was analyzed by a similar transwell as-
say, in which the porous membrane separating the two cham-
bers was covered with Matrigel, a commercial basal mem-
brane preparation. In this condition, treatment of SH-SY5Y
cells results in an increase of their invasive potential. Trans-
fection of anti-miR-10a and -10b resulted in a further increase
of the invasive potential of neuroblastoma cells, although in
the case of anti-miR-10b the differences are at the limit of
statistical significance (Fig. 5B). To study the effects of RA
treatment in the metastatic potential of neuroblastoma cells
and the involvement of miR-10a and 10b, we employed the
chicken chorioallantoic membrane assay. Given the complex-
ity of the assay, only anti-miR-10a and negative control anti-
miR were compared. In the chicken chorioallantoic mem-
brane assay, neuroblastoma cells transfected with negative
control anti-miR appeared to disseminate to the lungs when
transferred to the upper chorioallantoic membrane of 10-day-
old chicken embryos, and transfection of anti-miR-10a
slightly increased the presence of neuroblastoma cells in the
lungs. RA treatment of cells transfected with negative control
anti-miR significantly reduced the presence of human cells in
the chicken lungs. However, when RA treatment was admin-
istrated to cells transfected with anti-miR-10a the observed
RA-dependent reduction in lung metastasis was abolished
(Fig. 5C). Taken together, the results support an involvement
of miR-10a and -10b in the reduction of biological aggressive-
ness elicited by RA treatment in neuroblastoma cells.
Identification and Validation of Direct Targets of miR-10a
and -10b in SH-SY5Y Neuroblastoma Cells—Although the
HOXD10 gene is reportedly a functional target of miR-10a in
breast cancer cells (56, 57), we could not detect alteration of
HOXD10 protein levels after RA treatment or transfection of
anti-miR-10a and -10b in SH-SY5Y neuroblastoma cells (data
not shown). To identify new direct targets of miR-10a and
-10b during RA-induced differentiation of neuroblastoma
cells, a bioinformatic approach based on mRNA and miRNA
data integration was performed. A list of common predicted
targets by three databases, miRbase targets (58, 59), Tar-
getscan (60), and Pictar (61), was crossed with a list of down-
regulated mRNAs at 48 h of RA treatment obtained from an
Affymetrix microarray experiment.6 In this approach the
down-regulated mRNA group upon RA treatment was chosen
considering themRNA destabilization role of manymicroRNAs.
In addition, only 3-UTR seed sequences evolutionarily
conserved in the mRNAs were chosen. After evaluating the
resulting list, the top-seeded genes were two members of the
arginine/serine-rich SR splicing factor family: SFRS1 (SF2/
ASF) and SFRS10 (TRA2B) (Fig. 6, A and B; see also supple-
mental Figs. S2 and S3). To find out whether miR-10a and
miR-10b target the 3-UTR of SFRS1 and SFRS10 mRNAs, we
constructed luciferase gene based reporters including the 3-
UTRs of SFRS1 and SFRS10mRNAs. Co-transfection of these
reporters together with precursor pre-miR-10a and -10b in
HeLa cells resulted in80% reduction in the activity of the
reporter constructs, as compared with the control pre-miR-
transfected samples (Fig. 6, C and D). Conversely, co-transfec-
tion of specific anti-miR-10a and -10b enhanced the activity
of the SFRS1 3-UTR reporter construct, as compared with
the control anti-miR. However, only anti-miR-10b could en-
6 S. Meseguer, N. Ruiz, and D. Barettino, unpublished results.
FIGURE 4. Experimental reduction of miR-10a and -10b levels impaired
gene expression changes associated with RA-induced differentiation.
Shown is Western blot analysis of the protein levels for ID2 (A) and the
neuronal markers neurofilament medium polypeptide (NEFM, B) and
tyrosine hydroxylase (TH, C) after RA treatment of SH-SY5Y cells trans-
fected with anti-miR-10a and -10b and NC anti-miR. For comparison, the
results obtained with mock-transfected cells treated with vehicle (mock)
or with RA (mockRA) are shown. The filter was re-probed for -actin as
loading control.
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hance the reporter construct including the SFRS10 3-UTR,
whereas anti-miR-10a, although showing a similar trend, was
at the limit of significance (p 0.059) (Fig. 6, E and F). To test
the specificity of those effects, SFRS1 and SFRS10 3-UTRs
were cloned in the opposite direction into the luciferase re-
porter plasmids. Under those conditions the effects of anti-
miR-10a and -10b as well as those of pre-miR-10a and -10b
were abolished or severely diminished (data not shown).
Alteration of the Expression Levels of SFRS1 mRNA and Pro-
tein through Silencing or Forced Expression of miR-10a/-10b
in HeLa and SH-SY5Y Cells—Transfection of anti-miR-10a
and -10b to HeLa cells resulted in a80% reduction of the
endogenous miR-10a and -10b levels, as compared with nega-
tive control anti-miR (Fig. 7, A and B). These reduced miR-
10a and -10b levels led to an increase of the endogenous
SFRS1 protein expression, as compared with the negative
control anti-miR-transfected cells (Fig. 7C). miRNA action at
the post-transcriptional level occurs through translational
suppression and/or mRNA destabilization. To elucidate
which of the two mechanisms was responsible for SFRS1 reg-
ulation, SFRS1 mRNA expression was determined in anti-
miRs-transfected cells by quantitative RT-PCR. As shown in
Fig. 7D, an increase of SFRS1 mRNA in anti-miR-10a-trans-
fected cells occurred, as compared with negative control anti-
miR, whereas transfection of anti-miR-10b shows a similar
trend, although the differences are not statistically significant.
The results suggest the involvement of mRNA destabilization
in the regulation of SFRS1 levels. SFRS1 regulation by miR-
10a/-10b during RA-induced differentiation of SH-SY5Y cells
also occurred through mRNA destabilization. Relative SFRS1
mRNA and protein levels were determined after RA treat-
ment of anti-miR-transfected neuroblastoma cells. As shown
FIGURE 5. Involvement of miR-10a and -10b on the effects of RA inmigratory, invasive, andmetastatic potential of neuroblastoma cells. A, migra-
tion is shown. Mock-transfected cells and cells transfected with NC anti-miR, anti-miR-10a, or anti-miR-10b were treated with 1 M RA or vehicle for 96 h.
Cells from the different treatment groups were labeled with calcein AM, and migration transwell assays were set as described under “Experimental Proce-
dures.” The graph shows a representative experiment performed in triplicate (mean S.D.). Statistical significance was analyzed by comparing samples
transfected with anti-miR-10a and -10b with those transfected with NC-anti-miR. B, invasion is shown. Mock-transfected cells and cells transfected with NC
anti-miR, anti-miR-10a, or anti-miR-10b were treated with 1 M RA or vehicle for 96 h. Cells from the different treatment groups were used to set transwell
Matrigel invasion assays as described under “Experimental Procedures.” The graph shows the average of three experiments performed in triplicate (mean
S.D.). Statistical significance was analyzed by comparing samples transfected with anti-miR-10a and -10b with those transfected with NC-anti-miR. C, metas-
tasis is shown. Cells transfected with NC anti-miR or anti-miR-10a were treated with 1 M RA or vehicle for 96 h. Cells from the different treatment groups
were transferred to the upper chorioallantoic membrane (CAM) of 10-day-old chicken embryos and the number of metastasized cells into the lungs was
evaluated 7 days later as described under “Experimental Procedures.” The graph represents the values obtained from six parallel assays (mean S.D.). Sta-
tistical significance was analyzed by comparing samples transfected with anti-miR-10a with those transfected with NC-anti-miR. In addition, samples trans-
fected with NC-anti-miR treated with vehicle were compared with those treated with RA.
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in Fig. 7, E and F, SFRS1 mRNA and protein levels were
down-regulated in parallel during RA treatment of SH-SY5Y
cells. In contrast, abolishment of this down-regulation was
observed in RA-treated anti-miR-10a- and -10b-transfected
cells as compared with the control anti-miR-transfected cells.
Conversely, we want to determine whether an overexpression
of miR-10a and miR-10b in HeLa cells could have the oppo-
site effect in SFRS1 mRNA and protein levels. HeLa cells were
transiently transfected with pre-miR-10a and pre-miR-10b or
negative control pre-miR. Almost a 4000-fold increased ex-
pression of miR-10a and 7000-fold increased expression of
miR-10b was obtained in specific pre-miR-transfected cells as
compared with the negative control (Fig. 8A and B). Under
those conditions a significant reduction in SFRS1 protein and
mRNA levels was observed in pre-miR-10a-transfected HeLa
cells as compared with negative control pre-miR-transfected
cells. Nevertheless, reduction to a lesser extent was observed
in pre-miR-10b-transfected cells (Fig. 8, C and D). A similar
effect was observed in SH-SY5Y cells, in which transfection of
pre-miR-10b resulted in significant reduction of SFRS1
mRNA and protein levels, whereas the effect of pre-miR-10a
was in this case less important and, in the case of mRNA lev-
els, at the limit of statistical significance (p 0.07) (Fig. 8, E
and F).
Experimental Alteration of miR-10a and -10b Expression
Levels Impaired the Functions of SFRS1 in the Regulation of
Alternative Splicing and Specific mRNA Translation—SFRS1
(SF2/ASF) has important functions in the regulation of alter-
FIGURE 6. Identification and validation of SFRS1- and SFRS10 -3-UTRs as direct targets of miR-10a and -10b. A and B, shown is the location of the
putative miR-10a and -10b target sites in SFRS1 (A) and SFRS10 3-UTR (B). Unpaired bases are indicated in lowercase above and below the duplex. The pre-
dicted 	G value for this structure is calculated by mFold analysis. Nucleotide numberings in human SFRS1 and SFRS10 mRNAs are according to the corre-
sponding RefSeq entries (NM_006924 and NM_004593, respectively). C and D, shown are the effects of miR-10a and -10b overexpression on the activity of
SFRS1- (C) and SFRS10–3-UTR (D) luciferase reporter constructs in HeLa cells. HeLa cells were co-transfected with pre-miR-10a and -10b or negative control
pre-miR. Values (mean S.D.) are represented as relative light units obtained from three independent experiments performed in triplicate. Student’s t test
was used to compare samples transfected with pre-miR-10a and -10b to those transfected with negative control pre-miR. E and F, effects of miR-10a and
-10b silencing on the activity of SFRS1- (E) and SFRS10–3-UTR (F) luciferase reporter constructs in HeLa cells. HeLa cells were co-transfected with anti-miR-
10a and -10b or negative control anti-miR. Values (mean S.D.) are represented as relative light units obtained from an experiment performed in triplicate.
Statistical analysis was performed by comparing samples transfected with anti-miR-10a and -10b to those transfected with negative control anti-miR; ns,
non-significant.
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native splicing and in enhancing translation initiation of
mRNAs containing specific SFRS1 binding sequences (34,
62, 63). We wanted to evaluate whether regulation medi-
ated by miR-10a and -10b through the alteration of SFRS1
protein levels could result in altered regulation of the func-
tional processes where SFRS1 is involved. SFRS1 partici-
pates in the regulation of alternative splicing of tau exon
10 through an exonic splicing element, and this splicing
event is altered in specific pathological situations (64). Re-
duction of SFRS1 levels by transfection of pre-miR-10a and
-10b to SH-SY5Y neuroblastoma cells resulted in a reduc-
tion of the inclusion of exon 10, as shown by RT-PCR with
specific tau exon 10-flanking primers (Fig. 9, A and B). To
test the influence of miR-10a and -10b regulation on
SFRS1-dependent translational enhancement, we used a
translation reporter containing a luciferase coding se-
quence harboring the exonic splicing enhancer (ESE) from
the fibronectin extra domain A (EDA-ESE; pLCS-EDA) or
a mutant version of the ESE (pLCS-EDAmt) that does not
bind SFRS1 (Fig. 9C and Ref. 34). HeLa cells were co-trans-
fected with pLCS-EDA or pLCS-EDAmt together with pre-
miR-10a, pre-miR-10b, or negative control pre-miR. The
relative luciferase activity from pLCS-EDA over that ob-
tained from pLCS-EDAmt in a parallel experiment was
measured. The effect of the EDA exonic splicing enhancer
results in a close to 5-fold enhancement of translation.
Transfection of pre-miR-10a and -10b produced a severe
reduction in reporter gene translation (approximately to
40%), whereas transfection of control pre-miR did not af-
fect reporter translation (Fig. 9D). Our results are compati-
ble with a reduction of the alternative splicing enhance-
ment and translation activation functions through reduced
SFRS1 levels mediated by increased miR-10a or -10b
levels.
FIGURE 7.miR-10a/-10b knockdown leads to increased SFRS1 protein andmRNA levels in HeLa and SH-SY5Y cells. A and B, RT-qPCR analysis of
miRNA-10a (A) and -10b (B) endogenous expression levels after transfection of HeLa cells with anti-miR-10a, and -10b as compared with NC anti-miR is
shown. C, Western blot of SFRS1 protein expression after anti-miR-10a and -10b and NC-anti-miR transfection of HeLa cells is shown. The blot was reprobed
with -actin antibodies as the loading control. D, RT-qPCR analysis of SFRS1 mRNA levels in the same conditions is shown. The graph shows expression lev-
els relative to that of cells transfected with NC-anti-miR (mean S.D. of a triplicate experiment). E, Western blot of SFRS1 protein expression after anti-miR-
10a and -10b and NC-anti-miR transfection of SH-SY5Y cells followed by 1 M RA treatment is shown. The blot was reprobed with -actin antibodies as
loading control. F, RT-qPCR analysis of SFRS1 mRNA levels in same conditions is shown. The graph shows expression levels relative to that of RA untreated,
NC-anti-miR-transfected cells (mean S.D. of a triplicate experiment). Statistical analysis for panels A, B, D, and Fwas made by comparing the values from
cells transfected with anti-miR-10a or -10b to those from cells transfected with NC-anti-miR; ns, non significant.
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DISCUSSION
The discovery of a new class of regulatory elements named
microRNAs have contributed to add a new level of complexity
in the regulation of many biological processes, including neu-
ronal differentiation. Despite impressive progress made dur-
ing the last years in elucidating the molecular mechanisms of
RA-mediated transcriptional regulation, little is known about
the influence of RA signaling on microRNA regulation. In this
study we have identified 42 different miRNA species that sig-
nificantly change their expression levels (26 up-regulated and
16 down-regulated) during RA treatment of the SH-SY5Y
neuroblastoma cell line, which is considered a good model for
studying neuronal differentiation. After studying the reported
aspects of the members of this miRNA set, we have found that
some miRNA species (miR-10a, -10b, -132, -212, 211, -22,
-154,-26, -296, -422a, -378, and -107) reportedly participate in
differentiation in several contexts (65–74), although only
miR-132/212 seems up to now to be specifically involved in
neuronal differentiation (6, 72, 75). We have focused on the
functional study of two closely related microRNAs, miR-10a
and -10b, that showed the most prominent up-regulation
upon RA treatment. Up-regulation of miR-10b was previously
reported in RA-induced neuronal differentiation of human
embryonal carcinoma NT2/D1 cells (76), and an increase in
miR-10a could be detected during RA-induced differentiation
of mouse embryonic stem cells into smooth muscle cells (68).
This work reports that RA acts through NF-B binding to a
consensus element in miR-10a gene promoter to induce miR-
10a expression. In addition, some putative consensus RA reg-
ulatory elements could be detected in the promoter regions of
miR-10a and -10b genes (data not shown). All this evidence
suggests that RA signaling might be involved in miR-10a and
-10b regulation. Our analysis of the functional effects of miR-
10a and -10b knockdown showed that miR-10a and -10b are
key players in the regulation of RA-induced differentiation.
We have seen that both morphological changes associated
with RA differentiation and the regulation of the expression
of some differentiation markers were impaired in RA-treated
and anti-miR-10a and -10b-transfected cells. Additionally, we
have demonstrated that miR-10a and -10b expression was
necessary for the associated reduction in migratory and inva-
sive and metastatic activities. Although some reports indicate
FIGURE 8.miR-10a and -10b overexpression leads to a reduction of SFRS1 protein expression in HeLa and SH-SY5Y cells through a decrease of its
mRNA levels. A and B, shown is RT-qPCR analysis of miRNA-10a (A) and -10b (B) endogenous levels after transfection of HeLa cells with pre-miR-10a and
-10b as compared with NC pre-miR. C, Western blot analysis of SFRS1 protein expression in HeLa cells after transfection of NC pre-miR, pre-miR-10a, or pre-
miR-10b. The blot was reprobed with -actin antibodies as the loading control. D, RT-qPCR analysis of SFRS1 mRNA expression under the same conditions is
shown. The graph shows expression levels relative to those of cells transfected with NC-pre-miR (mean S.D. of a triplicate experiment). E, shown is a West-
ern blot of SFRS1 protein expression after pre-miR-10a and -10b and NC-pre-miR transfection of SH-SY5Y cells. The blot was reprobed with -actin antibod-
ies as loading control. F, RT-qPCR analysis of SFRS1 mRNA levels under the same conditions is shown. The graph shows expression levels relative to those of
RA-untreated, NC-pre-miR-transfected cells (mean S.D. of a triplicate experiment). Statistical analysis for panels A, B, D, and Fwas made by comparing the
values from cells transfected with pre-miR-10a or -10b to those from cells transfected with NC-pre-miR; ns, not significant.
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that miR-10a and -10b have a role in cancer pathogenesis and
metastatic spread (57, 77, 78), our findings together with an-
other study (79) give support to the idea that miR-10a and
-10b could act as tumor suppressor genes that opposite to
tumor malignancy.
On the basis of our results, we have confirmed the SR-fam-
ily splicing factor 1, SFRS1 (SF2/ASF), as a novel target for
miR-10a and -10b action. SFRS1 is a proto-oncogene with
deregulated expression in many tumors, and its expression,
like in other splicing factors, seems to be fine-regulated by
multiple post-transcriptional and translational mechanisms
(80). In this context, a recent publication described the in-
creased complexity of SFRS1 regulation by the existence of a
negative feedback loop in which SF2/ASF may promote miR-7
processing and mature miR-7 could bind to the 3-UTR of
SF2/ASF to repress its translation (81). Here we propose miR-
10a and -10b as new players in the complex regulation of
SFRS1 protein through a mechanism involving enhanced
mRNA cleavage. In addition, we showed how changes in miR-
10a and -10b expression levels may influence some molecular
activities in which SFRS1 is involved, such as translation en-
hancement of certain mRNAs and alternative splicing. In this
context, first using a transfection-based translation reporter
assay, we have shown how SFRS1 activity in translation could
be controlled by regulation of miR-10a and -10b levels. How-
ever, this is not the first evidence that provides miR-10a a role
in regulating translation. It has already been reported that
miR-10a may bind to the 5-UTRs of ribosomal protein
mRNAs and enhance their translation and, in consequence,
global protein synthesis under the conditions of amino acid
starvation or translational induction after anisomycin treat-
ment or overexpression of RAS (82). Our findings and the
previous work suggest a special role of miR-10a in controlling
translation of some mRNAs through negative regulation of
the SFRS1 protein level via 3-UTR mRNA binding or positive
regulation of the ribosomal protein level via 5-UTR mRNA
binding depending on the cellular context. We have also re-
ported that the activation of signaling pathways by RA treat-
ment results in rapid changes in the phosphorylation pattern
of SR proteins, including SFRS1. Subsequently, changes in
alternative splicing selection and an increase of the translation
of mRNAs containing SFRS1 binding sites take place (35). In
this context the reduction in SFRS1 levels induced through
miR-10a and -10b regulation could be interpreted as the clos-
ing of the feedback regulatory loop of RA on the activities of
SFRS1.
Moreover, we reported how a splicing event in the tau
gene, in which the exon 10 is included, could be altered by
regulation of miR-10a and -10b levels. This result demon-
strated once more that SFRS1 protein level needs to be pre-
cisely controlled during its activities for normal cell physiol-
ogy. In this sense, post-transcriptional regulatory mechanisms
are considered to be responsible of the diversification and
spatiotemporal control of the proteome during the establish-
ment of precise neuronal connectivity (83). Because an
mRNA is transcribed, it is subjected to different molecular
processes that include extensive structural regulation to ex-
pand the protein repertory through alternative splicing, RNA
packing into neuronal transport granules, and recognition by
RNA-binding proteins and/or microRNAs, which gives the
possibility of restricting protein synthesis to selective loca-
tions and under specific input conditions. This ability of the
FIGURE 9. Experimental alteration of miR-10a and -10b levels resulted in an impairment of SFRS1 functions in the regulation of alternative splicing
and specific mRNA translation. A, alternative splicing of tau protein exon 10 is altered by transfection of anti-miR-10a and -10b. RT-PCR was performed on
RNA extracted from anti-miR-10a and -10b or NC anti-miR-transfected SH-SY5Y cells. tau Exon 10 flanking primers were used in the RT-PCR reaction accord-
ing to Kondo et al. (64). B, quantification of the percentage of exon 10 inclusion is shown. The graph shows the value (mean S.D.) from three independent
experiments. Statistical analysis was made by comparing the values from cells transfected with pre-miR-10a or -10b to those from cells transfected with
NC-pre-miR. C, a schematic representation of the reporter genes used for the analysis of mRNA translation regulation is shown (adapted from Sanford et al.
(34)). D, the effect of the alteration of miR-10a and -10b levels on the translation of the LCS-EDA luciferase reporters is shown. Neuroblastoma cells were
transfected in parallel reactions with either the LCS-EDA or the LCS-EDAmt Luciferase reporters and the corresponding pre-miR-10a and -10b or NC-pre-miR
together with a promoter-less Renilla luciferase reporter as internal control. After transfection, luciferase activities were determined, and the ratio
between the normalized activities of the LCS-EDA and the LCS-EDAmt reporters is represented in the graph for the different transfection groups (mean
S.D. of two triplicate experiments). Statistical analysis was made by comparing the values from cells transfected with pre-miR-10a or -10b to those from cells
transfected with NC-pre-miR.
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post-transcriptional machinery to control the usage of pro-
teins in spatial and temporal manner suggests the existence of
a coordinated cross-talk between all the post-transcriptional
processes. Consistent with this idea, several studies confirmed
the presence of a splicing-microRNA interaction during dif-
ferentiation (84, 85). For instance, it has been reported that
the neuron-specific microRNA miR-124 directly targets
PTBP1mRNA, which it is a global repressor of alternative
pre-mRNA splicing in non-neuronal cells, resulting in the
transition from non-neural-specific to neural-specific alterna-
tive splicing patterns (85). Therefore, the changes in the levels
of SFRS1 would contribute to the establishment of a neural-
specific alternative splicing pattern and, therefore, to neural
differentiation. Supporting this idea, we have shown that re-
ducing SFRS1 mRNA levels due to the up-regulation miR-10a
and -10b expression may affect functions involved in the es-
tablishment of a specific gene expression program during RA-
induced differentiation of SH-SY5Y cells.
In summary, we have shown that exposure of neuroblas-
toma cells to RA causes prominent changes in miRNA expres-
sion. Two close related miRNAs, miR-10a and -10b, showed a
robust induction and appeared to be important in RA-in-
duced differentiation and in the associated changes in migra-
tory and invasive activities. The discovery of SFRS1 as direct
target of miR-10a and -10b support the emerging functional
interaction between two post-transcriptional mechanisms,
microRNAs and splicing, in the neuronal differentiation
context.
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